ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
29 janv. 2024 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
08 janv. 2024 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of...
Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices
19 déc. 2023 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, today announced the publication of a...
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
09 nov. 2023 16h17 HE
|
ProSomnus Sleep Technologies, Inc.
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
31 oct. 2023 16h05 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its third quarter...
ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference
03 oct. 2023 16h05 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announces...
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
21 sept. 2023 08h30 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced...
ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences
14 sept. 2023 08h30 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced that their...
Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea
23 août 2023 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
Precision oral appliance therapy effective among 90% of moderate and 85% of severe OSA patients In an Intent-to-Treat analysis, precision OAT demonstrated twice the mean disease alleviation as...
ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results
03 août 2023 08h09 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”) (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”),...